Morgan Stanley analyst Terence Flynn has maintained their bullish stance on ABBV stock, giving a Buy rating on May 21. Terence Flynn has given his Buy rating due to a combination of factors surrounding AbbVie’s strong financial outlook and promising developments in their product pipeline.
What happened to AbbVie (abbv)?
The latest trading session saw AbbVie (ABBV) ending at $160.19, denoting a -0.65% adjustment from its last day's close. This change lagged the S&P 500's 0.11% gain on the day. On the other hand, the Dow registered a loss of 0.3%, and the technology-centric Nasdaq increased by 0.56%.
What is AbbVie's average price target?
This current average has decreased by 0.66% from the previous average price target of $190.75. A clear picture of AbbVie's perception among financial experts is painted with a thorough analysis of recent analyst actions.
